Thrombocytopenia has been associated with type II bovine viral diarrhea virus (BVDV) infection in immunocompetent cattle, but the mechanism is unknown. The purpose of the present study was to develop and characterize a model of type II BVDV-induced thrombocytopenia. Colostrum-deprived Holstein calves were obtained immediately after birth, given a BVDV-negative and BVDV antibody-negative plasma transfusion, housed in an isolation facility, and randomly assigned to either control (n ϭ 4) or infected (n ϭ 5) groups. Infected calves were inoculated by intranasal instillation on day 3 of age with 10 7 TCID 50 of the prototype type II isolate, BVDV 890, whereas control calves were sham inoculated. Blood counts and virus isolations from serum, white blood cells, and platelets were performed daily until day 12 after infection, at which time all experimental calves were euthanatized, and pathologic, virologic, and immunohistochemical examinations were performed. On physical examination, the control calves remained normal, but the infected calves developed pyrexia and diarrhea characteristic of type II BVDV infection. The platelet count decreased in all infected calves, and a statistically significant difference in the platelet count between control and infected calves was observed on days 7-12 after infection. In addition, the mean platelet volume and white blood cell counts also decreased. Examination of the bone marrow from the infected calves revealed immunohistochemical staining for BVDV antigen in megakaryocytes and evidence of concurrent megakaryocyte necrosis and hyperplasia.
Bovine viral diarrhea virus (BVDV) is an important pathogen of cattle, resulting in worldwide economic losses. Outbreaks of severe, peracute disease in adult cattle and calves were reported in 1993 in the United States and Canada. 8, 12, 27 These outbreaks, which involved beef, dairy, and veal operations, were characterized by fever, diarrhea, abortion, leukopenia, thrombocytopenia, and death. Prior to 1993, it was generally believed that acute infections with BVDV resulted in mild disease, without considerable mortality. 2 The BVDV isolates from these outbreaks were analyzed, and the type II genotype of BVDV was identified. 8, 27, 30 Although type I and type II BVDV can be involved in the entire spectrum of clinical disease from subclinical to severe disease, the hemorrhagic disorder characterized by thrombocytopenia has been observed only with type II isolates of BVDV (S. R. Bolin, personal communication).
Thrombocytopenia associated with type II BVDV infection has been reported under natural 30 and experimental conditions. 5, 6, 9, 10, 13 Although previous experimental studies on type II BVDV infection have characterized the hemorrhagic syndrome, they have been descriptive in nature, and the mechanism of the BVDV-induced thrombocytopenia remains unknown. Several of the previous studies on BVDV-induced thrombocytopenia used an infection protocol that did not allow quantitation of the infectious dose of virus, which makes reproduction of their model difficult. 5, 9, 10 Furthermore, several studies failed to use controls or failed to use age-matched controls. 6, 9, 10 Control calves are critical in the evaluation of thrombocytopenia because of the variation in the normal platelet count; 26, 33 and age-matching is important because the platelet count varies between calves of different ages. 26, 32, 36 Finally, some investigations have used type II BVDV isolates that failed to consistently induce thrombocytopenia in all infected calves. 10, 13 Because it is difficult to reproduce these studies, no model of type II BVDV is available to study the thrombocytopenic aspect of type II BVDV infection.
The mechanism of increased virulence with some type II isolates of BVDV is currently unknown; however, the ability of type II BVDV to cause severe clinical disease and death is due, at least in part, to thrombocytopenia and the resulting hemorrhagic syndrome. The purpose of this study was to characterize the clinical, hematologic, virologic, and pathologic features of the thrombocytopenic BVDV infection in neonatal calves and to develop a model to study the pathogenesis of type II BVDV-induced thrombocytopenia.
Materials and methods
Animals. Colostrum-deprived newborn male Holstein calves were obtained immediately after birth from local dairy farms. Calves were moved to an isolation facility, randomly allocated to control or treatment groups, and individually housed in separate rooms. All calves were given a physical examination, and both serum and whole blood were obtained for virus isolation and serum was obtained for BVDV antibody by virus neutralization. All calves positive for BVDV by virus isolation or with serum antibody levels to BVDV greater than 16 were excluded from the study. The calves were given, by intravenous administration, 400 ml of fresh frozen plasma obtained from a BVDV antibody-negative and virus-negative donor cow. Calves were given parenteral vitamins A and D, a vitamin E and selenium, b and a commercial oral monoclonal antibody preparation against Escherichia coli K99 pilus antigen, b and were fed a nonmedicated milk replacer according to label directions at 12% of body weight twice daily. Each calf was examined twice daily, and the rectal temperature and the physical examination findings were recorded. Prior to initiation of the study, criteria for euthanasia were established. Calves demonstrating any one or a combination of the following were euthanatized: complete anorexia, recumbency with inability to rise, dehydration in excess of 12% of body weight, and hemorrhagic diathesis. No calf met these criteria; therefore, no calf was euthanatized prior to the completion of the study.
Virus and challenge protocol. The noncytopathic type II BVDV isolate 890, c which has been previously shown to induce thrombocytopenia in calves, 6 was used for the experimental infection of calves. The BVDV isolate 890 was propagated in bovine turbinate cells in Eagle's minimum essential medium (EMEM) d containing 10% fetal equine serum (FES), e L-glutamine, f penicillin G e (100 units/ml), and streptomycin e (100 g/ml). After a 3-day adjustment period in the isolation facility, calves in the infected group (n ϭ 5) were inoculated by intranasal instillation with 10 7 TCID 50 of the BVDV 890 isolate. Control calves (n ϭ 4) were inoculated by intranasal instillation with a sham inoculum that was prepared from an uninfected cell culture lysate.
Clinical pathologic examination. Manual platelet and leukocyte counts were performed daily on whole blood. The manual counts were performed with a platelet and white blood cell microcollection system g and a hemocytometer. Automated complete blood counts, including the mean platelet volume, were performed with an electronic particle counter. h Automated counts were done at various times after infection but included days 0 and 12 after infection on all calves. Coagulation profiles (activated partial thromboplastin time, prothrombin time, fibrin degradation products, and fibrinogen) were performed with whole blood on days Ϫ2, 4, 10, and 12 of the experiment according to standard procedure in the Clinical Pathology Section, Veterinary Teaching Hospital, Michigan State University.
Isolation and purification of platelets for virus isolation and electron microscopy. Whole blood was collected every other day from the jugular vein into plastic syringes containing 1.0 ml of 3.8% (w/v) sodium citrate for each 9.0 ml of blood. Platelet-rich plasma was harvested by differential centrifugation. 35 Purification of platelets was achieved through gel filtration. Briefly, 1 l of 1 M prostaglandin E 1 e was added to 1 ml of platelet-rich plasma prior to cen-trifugation at 800 ϫ g for 15 min. The plasma was removed and the platelet pellet was resuspended in 1 ml Hanks' balanced salt solution (136 mM NaCl, 5.4 mM KCl, 0.44 mM KH 2 PO 4 , 0.34 mM Na 2 HPO 4 , 5.5 mM dextrose, pH 7.4). Platelets were then passed over a 10-ml Sepharose 4B column. e The flow-through fraction containing the platelets was collected and a manual platelet count was performed. The gel-filtered platelets were adjusted to a concentration of 200,000 platelets/l in EMEM containing 10% FES, L-glutamine, and antibiotics, subjected to 3 freeze/thaw cycles, and centrifuged for 10 min at 1,500 ϫ g. The supernatant was extracted and filtered through a sterile filter with an average pore diameter of 0.45 m i and stored at Ϫ80 C for later use in procedures to isolate BVDV.
For transmission electron microscopic examination of platelets, platelet-rich plasma was harvested. 35 Platelet-rich plasma suspensions were divided into 0.5-ml aliquots in glass cuvettes, held at room temperature for 30 min, and then warmed for 5 min at 37 C. A teflon-coated magnetic stir bar was added to the sample, and the cuvette was then placed into an aggregometer. j The platelets were allowed to equilibrate in the aggregometer at a stir speed of 900 rpm for 30 sec. At that time, 0.5 ml of 0.1% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, was added and the sample was allowed to continue stirring for 1 min. The contents of the cuvette were transferred to an Eppendorf tube and centrifuged for 20 sec at 12,800 ϫ g. The supernatant was discarded and 1.0 ml of 3.0% glutaraldehyde in 0.1 M cacodylate buffer was added. The platelet pellet was fixed in this solution for 6 hr, at which time the supernatant was discarded and 1.0 ml of 0.1 M cacodylate buffer was added. The samples were then processed for transmission electron microscopy according to standard procedure. 24 Pathologic examination. On day 12 after infection, all calves were euthanatized with a lethal injection of barbiturate. k A postmortem examination was performed and all gross postmortem lesions were recorded. Tissues collected for histopathologic examination included liver, spleen, lung, heart, small and large intestine, adrenal gland, kidney, thymus, tonsil, brain, spinal cord, mesenteric and bronchial lymph nodes, and bone marrow. All tissues were fixed in 10% neutral buffered formalin with the exception of bone marrow, which was also fixed in B-5 fixative. l After fixation, the tissues were trimmed, embedded in paraffin, sectioned at 6 m, and stained with hematoxylin and eosin according to standard procedure. To assess the numbers and morphology of the cell constituents, a detailed evaluation of the bone marrow was performed, including calculation of the number of megakaryocytes per high-power field and the myeloid : erythroid series ratio. 17 Five different high-power field areas were evaluated for each calf.
Virologic and serologic examination. Serum and whole blood were collected daily for detection of BVDV. The whole blood was processed by hypotonic lysis of the red blood cells to yield the white blood cells. 7 The isolated white blood cells were then resuspended in EMEM containing 10% FES, L-glutamine, and antibiotics. After 3 freeze/thaw cycles, the white blood cell preparations were centrifuged for 10 min at 1,500 ϫ g. The supernatant was extracted and filtered through a sterile filter with an average pore diameter of 0.45 m i and stored at Ϫ80 C.
To determine the tissue distribution of the virus, virus isolation was performed on bone marrow, thymus, spleen, bronchial and mesenteric lymph nodes, tonsil, ileum, cerebellum, spinal cord, lung, esophagus, liver, and pulmonary artery collected postmortem. Approximately 0.5 g of tissue was added to 4 ml of EMEM with 10% FES, L-glutamine, and antibiotics in a sterile mortar. Sterile sand was added and the tissue was homogenized by grinding with a pestle. The homogenized tissue sample was transferred into conical tubes and centrifuged for 30 min at 2,300 ϫ g. The supernatant was removed and filtered through a filter with an average pore diameter of 0.45 m. i After processing, tissue preparations were stored at Ϫ80 C.
The serum, white blood cell preparations, gel-filtered platelet preparations, and tissue preparations were thawed, and 25 l of each sample was inoculated in duplicate into wells on 96-well microtiter plates containing monolayers of bovine turbinate cells in EMEM with 10% FES, L-glutamine, and antibiotics. After 3 days of incubation at 37 C in humidified air containing 5% CO 2 , the bovine turbinate cells were stained for BVDV antigen by an immunoperoxidase monolayer assay. 25 Serology for BVDV was performed by a microtiter virus neutralization procedure. 7 Sera obtained on days 0 and 12 after infection from all experimental calves were tested for neutralizing antibodies to type II BVDV. Sera were inactivated for 30 min in a 56 C waterbath. Serial 2-fold dilutions, ranging from 1:4 to 1:4,096, were made for each serum sample in a 96-well microtiter plate. The amount of virus used per test well was 500 TCID 50 of the type II cytopathic isolate MSU-AHDL cp1080626. m Bovine turbinate cells were used as the indicator cells at a dilution of 15,000 cells per well. Each test included a back titration of the virus and positive and negative serum controls. The antibody titer was read as the highest dilution with complete inhibition of cytopathic effect.
Immunohistochemical and immunofluorescent antibody detection of BVDV antigen. Immunohistochemical staining for BVDV antigen was performed on paraffin-embedded sections of bone marrow, pulmonary artery, lung, and spleen with the monoclonal antibody 15C5 and an avidin-biotin complex immunoperoxidase technique as previously described. 15 The direct immunofluorescent antibody test for BVDV antigen was performed on fresh frozen tissue sections of bone marrow, pulmonary artery, lung, and spleen according to standard procedure in the Animal Health Diagnostic Laboratory, Michigan State University, with an anti-BVDV polyclonal antiserum conjugated to fluorescein isothiocyanate. n Statistical analysis. Differences in platelet and white blood cell counts, coagulation profile data, and rectal temperature measurements between control and infected calves were evaluated by Student's t-test. The virus isolation and virus neutralization data were analyzed by Fisher's exact test. A P-value Ͻ0.05 was considered statistically significant.
Results
Physical examination findings. None of the calves met the criteria for euthanasia during the study period. In the infected calves, appetite remained normal, but diarrhea, characterized by blood and mucosal casts, was a consistent finding in all infected calves. Diarrhea was first noticed on day 5 after infection (2 calves), and by day 7 after infection, all infected calves developed diarrhea that continued throughout the study. Pyrexia (rectal temperature Ͼ39.4 C) was observed in the infected calves from days 2 through 12 after infection. When compared with the control calves, the infected calves had significantly elevated rectal temperatures on day 2 and days 4-12 after infection (P Յ 0.05). No clinical sign of disease was noted in the control calves.
Clinical pathologic findings. The platelet count decreased to less than 200,000/l in all infected calves, and a platelet count of less than 100,000 platelets/l was observed in 3 of 5 infected calves during the study. The manual platelet count reached the lowest point in the infected calves on day 11 after infection, with a mean platelet count of 139,300 platelets/l (range, 98,000-178,000 platelets/l). This compares with a mean platelet count of 801,125 platelets/l (range, 642,000-825,000 platelets/l) in the agematched control calves (Fig. 1) . A significant decrease in the manual platelet count was observed from day 7 after infection to the end of the study in the infected calves when compared with the age-matched control calves (Fig. 1 ). Platelet size, as measured by the mean platelet volume, was significantly reduced in the in- * Denotes statistically significant differences between control and infected calves at day 12 after infection. † Blood counts were performed on day 0 after infection (day of inoculation); coagulation profiles were performed 2 days prior to inoculation.
‡ PT ϭ prothrombin time; APTT ϭ activated partial thromboplastin time; FDP ϭ fibrinogen degradation products.
fected calves as the study proceeded over time ( Table  1) .
The white blood cell counts decreased in the infected calves. White blood cell counts were significantly different between infected and control calves on day 6 and days 8-12 after infection. The leukopenia in infected calves was due primarily to a profound neutropenia ( Table 1 ). The numbers of all the other cell types on the white blood cell differential were within normal limits.
No significant difference was noted between control and infected calves in the activated partial thromboplastin time, prothrombin time, fibrin degradation products, and fibrinogen of the coagulation profile (Table 1).
Transmission electron microscopic findings. Ultrastructural evaluation of platelets demonstrated a population of platelets that was heterogeneous in size. Compared with the control calves, the infected calves had an overall decreased platelet size, but several very large platelets were observed (Fig. 2) . Vesiculation of the platelet plasma membrane was also observed in platelets from calves infected with type II BVDV.
Virologic and serologic findings. BVDV was not isolated from antemortem or postmortem samples collected from the control calves. In contrast, BVDV was isolated from white blood cells, platelets, and serum of all infected calves ( Table 2) . BVDV was demonstrated earliest in white blood cells, followed by platelets, and then serum. BVDV was isolated from all the tissues examined in all infected calves with the exception of bone marrow (BVDV was isolated from 4 of 5 infected calves) and the liver, cerebellum, and spinal cord (BVDV was isolated in 3 of 5 infected calves).
All control and infected calves had BVDV-neutralizing antibody titers of Յ8 on the day of inoculation. The BVDV-neutralizing antibody titers remained Յ8 on day 12 after infection in all control and infected calves with the exception of 1 infected calf in which the antibody titer was 16 at day 12 after infection.
Pathologic findings. Petechial hemorrhages were present in all infected calves, with the hemorrhages being most prominent in the rumen, abomasum, and/ or the endocardial surface of the heart. Oral erosions in the buccal mucosa were present in 3 of 5 infected calves. Abomasal edema, which was most prominent in the spiral folds of the fundus, was present in 4 of 5 infected calves. No significant lesions were present on gross postmortem examination of control calves.
Histologic evaluation of the bone marrow revealed differences between control and infected calves. Infected calves had more megakaryocytes per high-power field than the control calves (Table 3 ). In the infected calves, many of the megakaryocytes did not have uniform nuclear size or chromatin pattern. Approximately one-half of the megakaryocytes in infected calves were either immature or had undergone necrosis as evidenced by the loss of, or pyknosis of, the nuclei (Fig 3B) . The myeloid : erythroid series ratio was increased in the infected calves when compared with the control calves (Table 3) . Lymphoid depletion and reduced follicular size were present in the ileum and spleen in all infected calves. In the ileum, mild congestion of the mucosae and submucosae was present in 4 of 5 infected calves. In 3 of these calves, mild ulceration of the mucosae was present, and crypt abscessation was present in 1 calf. An occasional focus of necrosis of individual cells within the zona fasciculata of the adrenal gland was present in 4 of 5 infected calves and 1 control calf. Superficial erosions of the tongue with epithelial parakeratotic change, basal cell vacuolization with apoptosis, and mild submucosal inflammation were present in 4 of 5 infected calves. A mild angiopathy, characterized by deposits of eosinophilic protein on the surface of swollen endothelial cells, was observed in the cerebellum, cerebrum, brain stem, pulmonary artery, heart, and lung in 3 of 5 infected calves. In the lung, pulmonary edema fluid was present that distended the interlobular spaces. This lesion, which was pre- sent in all infected calves, was not associated with any significant inflammation.
Immunohistochemistry and immunofluorescent antibody testing. In the control calves, no evidence of BVDV antigen was detected by immunohistochemical or immunofluorescent antibody staining. However, there was immunohistochemical staining for BVDV antigen in all paraffin-embedded tissue sections collected for evaluation from all infected calves. In 3 of 5 infected calves, immunohistochemical and immunofluorescent antibody staining of bone marrow revealed the presence of BVDV-specific antigen in megakaryocytes (Fig. 3C, 3D ). Immunohistochemical staining for BVDV was also present in the smooth muscle of blood vessels located in the spleen, lung, and bone marrow. Mononuclear cells in the bone marrow, spleen, and lung and focal areas of lymphoid cells in the spleen also contained BVDV antigen.
Discussion
A model of type II BVDV-induced thrombocytopenia with newborn male Holstein calves was developed and characterized in this study. The principal advantages of this model over previous studies on BVDV-induced thrombocytopenia are the demonstration of a decreased platelet count in all infected calves, the use of age-matched controls to demonstrate statistically significant differences in platelet counts between control and infected calves, an intranasal infection protocol, and a standardized infectious dose of virus. The use of a virus-negative and BVDV antibody-negative plasma transfusion should be considered an additional advantage of this model. Because a plasma donor was vaccinated for the common neonatal infectious diseases, the calves acquired adequate immunity against these agents, and, thus, the loss of calves from the study due to sepsis, respiratory disease, and enteritis was prevented. This is particularly important because both sepsis and endotoxemia can cause thrombocytopenia in neonatal calves. 11, 32 Thrombocytopenia is defined as a reduction in the number of circulating platelets below the minimum normal level for the species. 19 Considerable variation exists in the literature concerning the platelet count in normal male Holstein calves, with one group of investigators reporting a range of 192,000-892,000 platelets/l 27 and another reporting a range of 480,000-1,200,000 platelets/l. 36 Therefore, defining thrombocytopenia on the basis of the literature is difficult. To circumvent these problems, age-, breed-, and sex-matched control calves were used in order to minimize the variation in the definition of thrombocytopenia and to demonstrate statistically significant differences in the platelet count between calves infected with type II BVDV and their matched controls. Although previous studies have demonstrated thrombocytopenia with different viral isolates, 5, 9, 10 different routes of inoculation, 5, 9, 10 and different ages and breeds of calves infected with BVDV, 5, 6, 9, 10 matched controls were not used. Thrombocytopenia (platelet count Ͻ192,000 platelets/l) and, more importantly, a significant difference in the platelet count between control and infected calves from days 7 through 12 after infection were demonstrated in this study. Additional justification for the use of age-matched controls is the fact that there appears to be an age-related change in the platelet count in neonatal calves. The platelet count in the age-matched control calves actually increased during the study, thus it is difficult to interpret a platelet count in an infected calf without the appropriate control. This change in platelet count has been alluded to in a previous study 32 in which the platelet count gradually increased from 212,050 Ϯ 73,945 platelets/ l at birth to 645,000 Ϯ 54,571 platelets/l by 4 days after birth.
In the present study, the mean platelet volume in infected calves was significantly decreased at day 12 after infection when compared with control calves. Ultrastructural evaluation of platelets by transmission electron microscopy also demonstrated that platelets were smaller in the infected calves; however, an increased heterogeneity in size of platelets was noted in the infected calves. The mean platelet volume can be used to help classify thrombocytopenia. 4 In general, platelets recently released into the bloodstream from the bone marrow are larger; therefore, the mean platelet volume is elevated when the thrombocytopenia is due to increased destruction of platelets. Conversely, aged platelets are smaller and mean platelet volume is decreased when the thrombocytopenia is due to decreased marrow production. 4 The low mean platelet volume in BVDV-induced thrombocytopenia suggests decreased production of platelets similar to that seen with human immunodeficiency virus infections and myelosuppressive disorders. 21 The platelet volume has also been reported as decreased in pigs undergoing classical swine fever virus infection (hog cholera virus), which is closely related to BVDV; however, the significance of that finding was unknown at the time. 38 Other antemortem characteristics of this model of BVDV-induced thrombocytopenia include pyrexia and diarrhea, which are consistent with previous reports regarding type II BVDV infection in calves. 5, 6, 9, 10 A decreased white blood cell count characterized by neutropenia has also been previously described with type II BVDV infection in immunocompetent calves. 10, 13 Lymphopenia and anemia, observed by some investigators, 10, 13 were not observed in this study. The myeloid : erythroid series ratio was increased in the infected calves, suggesting the bone marrow was increasing production of leukocytes. Coagulation profiles were within normal limits in this study, and normal findings were reported in a previous study on type II BVDV infection in calves. 10 The latter findings and the results of this study support the hypothesis that type II BVDV-induced thrombocytopenia is not likely to be due to disseminated intravascular coagulation.
An association of BVDV with platelets in the peripheral circulation was demonstrated in this study and other studies. 5, 6, 9 It has been suggested that platelets may serve as ''carriers'' of circulating virus. 9 This virus-platelet association may be responsible for the higher level of virulence seen with some type II isolates of BVDV because platelets may participate in a rapid dissemination of virus throughout the body. Megakaryocyte infection with BVDV was demonstrated, and this may be the origin of the BVDV-platelet association rather than through an extramedullary association in the peripheral blood.
BVDV antigen was demonstrated in megakaryocytes by immunohistochemistry in this study and other studies. 13, 23, 34 In addition to BVDV, several other viruses important in veterinary and human medicine can infect megakaryocytes. 1, 3, 14, 22, 28 The megakaryocyte is the hematopoietic precursor cell for platelets. 40 Although megakaryocytes comprise only 0.05% of the nucleated cells in the bone marrow, 16 they are responsible for maintaining the large circulating platelet population. Therefore, a decrease in the number of megakaryocytes during the early phase of type II BVDV infection, or disturbance in the maturation of megakaryocytes by a type II BVDV infection, could have a direct impact on the number of circulating platelets. The contribution of megakaryocyte infection to the development of thrombocytopenia with type II BVDV infection is unknown.
Previous studies on the histologic examination of bone marrow from type II BVDV-induced thrombocytopenic infections have been contradictory. Megakaryocyte necrosis 31 and adequate to increased numbers of megakaryocytes 29 have been reported. An experimental study on type II BVDV demonstrated bone marrow necrosis in 5 of 6 calves, and, in the remaining calf, megakaryocyte hyperplasia was observed in which immature megakaryocytes were present in relatively high numbers. 13 Both megakaryocyte degeneration and megakaryocyte hyperplasia were observed in this study. The number of immature megakaryocytes was increased, likely in response to the thrombocytopenia, and yet there were also numerous megakaryocytes undergoing pyknosis and degeneration. Viral infection of the bone marrow may be occurring during the initial stages of viremia, leading to a transient suppression of platelet production by the megakaryocytes.
Thrombocytopenia, regardless of the underlying etiology, results from only 3 basic mechanisms: decreased production, accelerated destruction, or abnormal sequestration of platelets. 37 Viruses have been associated with thrombocytopenia in humans and animals, 20, 41 but the underlying mechanisms are complex, multifactorial, and incompletely understood. Classical swine fever virus (hog cholera virus) induces thrombocytopenia and hemorrhage by multiple mechanisms including accelerated platelet destruction caused by direct damage to the platelets, virus-induced endothelial lesions, and disseminated intravascular coagulation; 38 however, megakaryocyte necrosis and degeneration have also been reported. 18 The mechanism of BVDVinduced thrombocytopenia may, like classical swine fever virus, involve a combination of 2 or more factors. However, in contrast to classical swine fever virus, decreased production of platelets as a result of megakaryocyte infection may be the predominant mechanism. Accelerated platelet destruction and abnormal sequestration of platelets as the cause of type II BVDV-induced thrombocytopenia are less likely on the basis of previous studies 5,6,10 and the findings of this study. Disseminated intravascular coagulation causes thrombocytopenia because of an accelerated destruction of platelets. 33 The presence of normal coagulation profiles found in this study and a previous study 10 suggests that disseminated intravascular coagulation is not involved in BVDV-induced thrombocytopenia.
In summary, a model of type II BVDV-induced thrombocytopenia has been developed and characterized. It appears likely that the thrombocytopenia associated with type II BVDV infection is due primarily to a decreased production of platelets. This model of thrombocytopenia may prove useful for elucidating the pathophysiology of the hemorrhagic syndrome associated with type II BVDV infection and help to determine what makes some type II BVDV isolates more virulent than others in immunocompetent cattle. helpful suggestions; Dan Taylor for expert technical assistance; and Ralph Common for photographic support. 
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